Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
Provided By GlobeNewswire
Last update: Feb 25, 2025
– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –
– KPL-387 Phase 1 single ascending dose data support potential monthly dosing –
Read more at globenewswire.com26.97
+1.09 (+4.21%)
Find more stocks in the Stock Screener
KNSA Latest News and Analysis
a day ago - ChartmillThese stocks are gapping in today's sessionLet's have a look at the gap up and gap down stocks in today's session.
